What a REMS is and what it requires of the pharmacy, the iPLEDGE isotretinoin program, medication guides, and the federal pseudoephedrine purchase limits.
REMS — Risk Evaluation and Mitigation Strategy
What Is REMS?
A REMS is an FDA-required safety framework used when ordinary labeling is not enough for a medication with serious risks. REMS authority was created by the Food and Drug Administration Amendments Act of 2007 (FDAAA 2007), which gave the FDA the power to require manufacturers to design and operate these programs as a condition of approval or continued marketing. The purpose is to reduce severe adverse outcomes while allowing appropriate patients to receive the drug. Depending on the product, a REMS program may add prescriber, pharmacy, patient, dispensing, or monitoring requirements.
Definition: A REMS is an FDA-mandated safety framework used when a medication needs extra controls to keep its benefits greater than its risks.
REMS programs are mandatory when the FDA requires them — they are not voluntary. Manufacturers cannot opt out.
REMS Elements (FDA Framework)
Per FDA's REMS framework (FDAAA 2007), a REMS may include one or more of the following elements, and must include a timetable for submission of assessments:
Medication Guide — FDA-approved written patient information that must accompany certain drugs.
Communication Plan — method for educating prescribers and other healthcare professionals about key risks.
ETASU (Elements To Assure Safe Use) — specific conditions that must be satisfied before prescribing, dispensing, or administering the product.
Implementation System — infrastructure used to track and enforce ETASU compliance.
Mnemonic: "MedGuide-or-PPI / Communication / ETASU / Implementation / Timetable" — the FDA REMS framework per current iPLEDGE Q&A is Medication Guide or Patient Package Insert, a communication plan, one or more elements to ensure safe use (ETASU), an implementation system, and a timetable for submission of assessments. The older "MCEI four-component" shorthand is incomplete — it omits the PPI alternative and the required timetable. Pair with "FDAAA 2007 — REMS Authority." See the Mnemonic Library cheat sheet Sections 1 and 10.
ETASU Examples
Prescriber and/or dispenser credentialing — often tied to training or certification.
Use of the drug only in designated care settings (for example, specified clinics or certified infusion centers).
Required patient monitoring, such as labs or therapeutic follow-up.
Patient enrollment in a registry or monitoring program while therapy continues.
Expanded Procedural Requirements
Obtaining a restricted REMS drug typically requires some combination of:
Prescriber enrollment or certification.
Pharmacy enrollment or authorization.
Patient-specific documentation.
Confirmation of the indication, dose, and quantity.
Program forms or patient acknowledgments, when required.
Some REMS programs subject participating pharmacies to audits or compliance reviews.
FDA Resources
The FDA site publishes the current REMS list; search for "Risk Evaluation and Mitigation Strategies (REMS)."
The REMS Public Dashboard (released by FDA in late 2021) provides interactive data on every active REMS program.
REMS@FDA displays REMS program data in tabular format — a quick-reference listing of product details, REMS materials, goals, updates, and assessments.
iPLEDGE® Program — Isotretinoin REMS
Covers all isotretinoin products: Absorica® (current branded product); Accutane® (legacy — discontinued by Roche in 2009 but the brand name remains colloquially common); generics Amnesteem®, Claravis®, Myorisan®, Zenatane®, and Sotret® (discontinued).
Two negative pregnancy tests required before starting therapy (patients who can become pregnant).
Monthly pregnancy testing during treatment.
Patients must use two forms of contraception.
Prescribers, pharmacies, and patients must all be registered in iPLEDGE®.
Prescription validity window — patients who can become pregnant:7 days. Unchanged.
Prescription validity window — patients who cannot become pregnant: a 30-day window currently applies. The FDA approved a modification on February 9, 2026 that eliminates this 30-day window; it takes effect November 15, 2026 (delayed from the originally planned August 8, 2026 date — the FDA pushed implementation back to allow iPLEDGE system testing, and exercises enforcement discretion until then). From that date forward, there is no prescription window for this category.
Program history and the 2026 modification (background): In December 2021, iPLEDGE® transitioned from sex-based categories ("females of reproductive potential" and "males and females not of reproductive potential") to the current sex-neutral categories — (a) patients who can become pregnant and (b) patients who cannot become pregnant. The FDA's February 9, 2026 modification (effective November 15, 2026 — delayed from the originally planned August 8, 2026 date) makes three student-facing changes that reduce administrative burden: (1) the 30-day prescription window for patients who cannot become pregnant is eliminated; (2) monthly counseling documentation for that category is no longer required (counseling still occurs at enrollment and prescriber discretion); (3) patients of reproductive age may complete pregnancy testing at home or in other non-medical settings with clinician approval. Until the November 15, 2026 effective date the prior rules — including that 30-day window and the monthly counseling documentation — remain in force. The two-negative-pregnancy-tests-before-start rule, monthly pregnancy testing, and two-forms-of-contraception rule are unaffected for patients who can become pregnant. Because iPLEDGE policy may keep evolving, confirm the current rules on exam day.
Exam Tip: Know the iPLEDGE® prescription-pickup window. Today it is 7 days for patients who can become pregnant and 30 days for those who cannot. The FDA's February 9, 2026 modification eliminates the 30-day window effective November 15, 2026, leaving the 7-day window as the only pickup window iPLEDGE® enforces.
Mycophenolate REMS — education-focused because of birth-defect concerns.
Opioid Analgesic REMS (umbrella program for IR and ER/LA opioids) and TIRF REMS — overdose risk and safe prescribing emphasis. Note: the legacy "ER/LA Opioid Analgesics REMS" was consolidated into the broader Opioid Analgesic REMS in late 2018; both terms appear on legacy exam materials. TIRF REMS is the distinct restricted-distribution program for transmucosal immediate-release fentanyl products. However, on August 28, 2024 the TIRF manufacturers announced that all TIRF products would be discontinued effective September 30, 2024 (FDA did not request the discontinuation). The REMS no longer accepts new enrollments and stays on record while the underlying approvals remain active.
Mifepristone REMS — dispensing allowed by or under the supervision of a certified prescriber, or by a certified pharmacy on a prescription from a certified prescriber. The 2023 REMS modification removed the in-person dispensing requirement and added a pharmacy certification pathway; retail pharmacies may dispense if they complete certification. FDA has conducted a REMS safety review of mifepristone. Because mifepristone REMS rules may continue to evolve, confirm the current rules with the FDA REMS@FDA database on exam day.
Esketamine REMS (Spravato®) — administered only in certified healthcare settings with at least 2-hour post-dose patient monitoring.
Clozapine monitoring — The FDA Advisory Committee voted November 19, 2024 to dismantle the Clozapine REMS. Two FDA dates appear in the record: the announced effective date (when REMS participation requirements ended for prescribers, pharmacies, and patients) was February 24, 2025; the FDA's formal rescission-of-record date followed on June 13, 2025. The February 24 date is the operationally relevant one for pharmacy technicians — that is when ANC-to-REMS reporting and REMS enrollment stopped being required, and it is the date the course and most flashcards anchor to. ANC (absolute neutrophil count) monitoring recommendations remain in the prescribing information and the Boxed Warning independent of REMS elimination; prescribers, pharmacies, and patients are no longer expected to participate in a REMS or report ANC values to a REMS system before dispensing.
Thalidomide Example Detail
The thalidomide REMS (Thalomid® REMS) exists to prevent fetal exposure and to ensure everyone involved understands the drug's severe risks.
Prescriber, pharmacy, and patient enrollment are all required.
The pharmacy must confirm that required program conditions were met before dispensing.
Program materials and documentation must be completed and retained.
Pregnancy exposure reporting and compliance review remain central safety expectations.
Limited-Distribution Drugs (LDDs)
Definition: LDDs are commercial products with restricted distribution. Limited distribution may reflect safety, monitoring, manufacturer channel control, or operational reasons; it is not limited only to small patient populations. The pathway to obtain an LDD is often described as a "limited-access" or "restricted-distribution" channel.
Why distribution is limited:
Track where the medication is stocked and dispensed.
Confirm that pharmacy staff complete required product-specific training.
Verify that ordered follow-up monitoring (for example, labs) is completed when the program requires it.
Manufacturers and distributors may apply extra distribution controls to these products, and some LDDs fall under FDA-required REMS.
LDDs by Therapeutic Area
Limited-distribution drugs cluster in a handful of therapeutic areas. Oncology is the largest, with agents such as pembrolizumab (Keytruda®) and enzalutamide (Xtandi®). Cystic fibrosis care depends heavily on the CFTR-modulator combinations, most prominently elexacaftor/tezacaftor/ivacaftor (Trikafta®). Chronic inflammatory diseases — psoriasis, rheumatoid arthritis, and related conditions — contribute biologics such as secukinumab (Cosentyx®) and tocilizumab (Actemra®). And the thalidomide-analog immunomodulators — thalidomide (Thalomid®), lenalidomide (Revlimid®), and pomalidomide (Pomalyst®) — move through tightly controlled channels paired with REMS oversight.
Relationship Between LDDs and REMS
Many LDDs also carry a REMS requirement determined by the FDA.
When both apply, the REMS program layers additional safety controls on top of the restricted distribution channel.
Medication Guides (MedGuides)
The FDA requires Medication Guides for certain drugs and drug classes.
A Medication Guide is FDA-approved patient information that explains serious risks, major adverse effects, and key use instructions in plain language.
When required, the MedGuide must accompany the prescription product at dispensing — every fill, regardless of whether the patient requests it.
Common outpatient examples include certain NSAIDs, many antidepressants, opioid products, stimulants and amphetamines, and some antiepileptics. Zolpidem (Ambien®) is a Medication Guide example.
CMEA Limits on Retail Pseudoephedrine Sales
Purpose
Enacted to prevent the illegal manufacture of methamphetamine and amphetamine from OTC precursor chemicals.
Regulated Substances
Ephedrine and pseudoephedrine — the active ingredients in common cough, cold, and allergy OTC products — are precursor chemicals to methamphetamine and amphetamine. Phenylpropanolamine was historically a CMEA precursor but is no longer marketed in the US.
Definition: CMEA is the federal law that limits and tracks retail sales of ephedrine- and pseudoephedrine-containing products.
Federal Purchase Limits
Federal law limits the amount a customer may purchase per day and during a 30-day period.
Limit
Amount
Daily maximum
3.6 g (retail and mail-order)
30-day maximum (retail)
9 g
30-day maximum (mail-order)
7.5 g
Tablet-count examples:
3.6 g daily limit = 3,600 mg
At 30 mg per tablet: 3,600 ÷ 30 = 120 tablets per day
At 60 mg per tablet: 3,600 ÷ 60 = 60 tablets per day
Exam Tip: 3-6-9. Daily 3.6 g, 30-day 9 g. Keep the two numbers tied. The base-versus-salt distinction is rarely tested — use straightforward tablet-strength math unless the question tells you otherwise.
Mnemonic: "3.6 / 9 / 30" + "CMEA 2005 — Combat Meth." Daily 3.6 g, 9 g per 30-day window. Single most-tested year-act pairing in Domain 2. See the Mnemonic Library cheat sheet Section 1.
Logbook Requirements
Purchasers must show a valid government-issued photo ID.
Purchasers must complete the required sales log, which may be kept electronically.
The logbook records the name of the purchaser, the address of the purchaser, the date and time of purchase, the product purchased and quantity sold, and the signature of the purchaser.
Law-enforcement agencies may review logbooks when investigating violations of sales restrictions.
State vs. Federal Law
States may add their own restrictions on these products beyond the federal baseline.
Federal requirements always apply nationwide.
When state law goes further than federal law, the pharmacy follows the stricter rule.
Storage Requirements
Ephedrine- and pseudoephedrine-containing products must be stored so the public cannot freely reach them — behind the pharmacy counter or in a locked area.
Patient Information Documents — Four Categories
Four different prescription-information documents serve overlapping but distinct purposes. The PTCE tests the distinctions directly.
Voluntary leaflet distributed with most retail prescriptions
General drug info prepared by the pharmacy or third-party vendor
PPI requirement: FDA requires the pharmacy to dispense a Patient Package Insert (PPI) with every fill of an estrogen or oral-contraceptive product. The PPI is written for the patient in plain language — distinct from the full Package Insert (PI), which is the clinician-directed prescribing information.
Common Trap: The Package Insert (PI) is for the clinician — not the patient. The PPI is federally required for estrogens and oral contraceptives. The Medication Guide must be provided whenever the FDA has mandated one — regardless of whether the patient asks. CMI is not federally mandated — it is the retail leaflet the pharmacy routinely prints alongside the prescription.
Black Box (Boxed) Warning
A Black Box Warning (BBW) — also called a Boxed Warning — is the FDA's strongest safety alert, reserved for drugs with risks of serious injury or death.
The warning appears on the drug's prescribing information (package insert) enclosed in a solid black border at the top of the label.
A BBW often triggers related requirements such as a Medication Guide or REMS.
Examples: long-acting opioids, fluoroquinolones (tendon rupture, aortic aneurysm), certain antidepressants (suicidality in pediatrics), antipsychotics (elderly dementia-related psychosis mortality), and anti-amyloid monoclonal antibodies in Alzheimer's therapy (ARIA).
MedWatch — FDA Adverse-Event Reporting
MedWatch is the FDA's voluntary safety-reporting program for healthcare professionals and consumers.
MedWatch accepts reports of serious adverse events, product quality problems, product use or medication errors, therapeutic inequivalence or failure, and suspected counterfeit medical products associated with FDA-regulated products.
Reports are submitted through the FDA MedWatch portal — Form 3500 for voluntary reports (healthcare professionals and consumers) and Form 3500A for mandatory manufacturer reports.
MedWatch is separate from VAERS (vaccines) and from manufacturer REMS reporting.
Common Traps
Here's where people miss it on Section 2.4. The chapter scatters these warnings inline as you read; this section pulls them together so they are easy to drill before the exam.
Confusing the four patient-information documents. The Package Insert (PI) — "full prescribing information" — is for the clinician, not the patient. The PPI is federally required for estrogens and oral contraceptives at every fill. The Medication Guide must be provided whenever the FDA has mandated one for that drug — regardless of whether the patient asks. CMI is the routine retail leaflet and is not federally mandated.
Mixing up the CMEA numbers. Pseudoephedrine limits are 3.6 g per day and 9 g per 30 days (retail). Anchor them as 3-6-9. The 30-day mail-order limit is 7.5 g.
Calling pseudoephedrine a controlled substance. Pseudoephedrine is not scheduled — it is a CMEA-regulated OTC precursor. It is stored behind the counter and logged, but it is not a controlled substance.
Treating REMS as a single template. REMS programs are tailored drug by drug. A REMS may include a Medication Guide or PPI, a Communication Plan, ETASU, and an Implementation System, and must include a timetable for submission of assessments. "REMS = MedGuide only" is wrong — many REMS add ETASU.
Confusing a Black Box Warning with a REMS. A Boxed (Black Box) Warning is a label warning — the FDA's strongest. A REMS is a comprehensive safety program. A BBW may trigger a Medication Guide or REMS, but the FDA decides drug by drug; a BBW does not automatically mean a MedGuide.
Assuming every limited-distribution drug is under a REMS. Some LDDs are restricted for channel control, reimbursement, or operational reasons with no formal REMS; others are both LDD and under REMS. The two are not the same thing.
Putting DHEA under the Anabolic Steroid Control Act. DHEA was explicitly exempted. It remains legally available OTC as a dietary supplement under federal law (some states restrict it independently).
Misidentifying the iPLEDGE prescription window. Patients who can become pregnant have a 7-day window (unchanged). Patients who cannot become pregnant currently have a 30-day window; the FDA's February 9, 2026 modification eliminates it effective November 15, 2026, after which there is no prescription window for that category.
Confusing MedWatch Form 3500 with 3500A.Form 3500 is for voluntary reports from healthcare professionals and consumers. Form 3500A is for mandatory manufacturer reports. MedWatch is also separate from VAERS (vaccines).
Letting state law slide when it is stricter than CMEA. States may add restrictions beyond the federal CMEA baseline. When state and federal rules differ, the pharmacy follows the stricter rule.
Quick Review Checklist
A fast scan of the highest-yield Section 2.4 facts. If any line does not land, go back to the matching body section before moving on.
CMEA — Combat Methamphetamine Epidemic Act, 2005; targets the methamphetamine/amphetamine precursors ephedrine and pseudoephedrine.
CMEA purchase limits — 3.6 g/day (retail and mail-order); 9 g/30 days retail; 7.5 g/30 days mail-order.
CMEA workflow — behind-the-counter or locked storage; valid government-issued photo ID; logbook (name, address, date/time, product, quantity, purchaser's signature), paper or electronic.
REMS — Risk Evaluation and Mitigation Strategy; FDA-mandated (not voluntary); authority from FDAAA 2007; exists to keep a drug's benefits greater than its risks.
REMS elements — Medication Guide or PPI, Communication Plan, ETASU (Elements To Assure Safe Use), Implementation System; all REMS include a timetable for submission of assessments.
iPLEDGE® — isotretinoin REMS to prevent fetal exposure; two negative pregnancy tests before start, monthly testing during treatment, two forms of contraception; prescribers, pharmacies, and patients all enroll.
iPLEDGE® prescription window — 7 days for patients who can become pregnant; 30 days for patients who cannot become pregnant, with that 30-day window eliminated effective November 15, 2026 by the FDA's February 9, 2026 modification.
Clozapine — the Clozapine REMS was eliminated; REMS participation ended February 24, 2025; ANC monitoring recommendations remain in the prescribing information and Boxed Warning.
Four patient-information documents — PI (clinician), PPI (estrogens/oral contraceptives, every fill), Medication Guide (FDA-mandated high-risk drugs, every fill), CMI (voluntary retail leaflet).
Black Box (Boxed) Warning — the FDA's strongest safety alert; solid black border on the prescribing information; reserved for risks of serious injury or death.
MedWatch — FDA adverse-event reporting; Form 3500 voluntary (professionals/consumers), Form 3500A mandatory (manufacturers); separate from VAERS.
LDDs — limited-distribution drugs; restricted channels for safety, monitoring, or operational reasons; some also carry a REMS.
State vs. federal — when CMEA and state law differ, the stricter rule governs.
Free Top 200 drugs sheet. Brand, generic, class,
all the controlled-substance schedules on one page, and the look-alike pairs — built by a
pharmacist who precepts technicians. No signup gate on the content itself.
Get the free sheet.